3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn's disease in Tunisian population

Inflammation Research

Volumn 58, Issue 4, 2009, Pages 218-223

  Marrakchi, R ^a   Bougatef, K ^a   Moussa, A ^b   Ouerhani, S ^a   Khodjet El Khil, H ^a   Messai, Y ^a   Mestiri, O ^a   Najar, T ^b   Benammar Elgaaeid, A ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

3020insC mutation; ASCA; CARD15 NOD2; Crohn's disease; Inflammatory bowel disease

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; FUNGUS ANTIBODY;

ALLELE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE INSERTION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; ILEUM; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; TUNISIA; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, FUNGAL; CROHN DISEASE; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; ILEUM; MUTAGENESIS, INSERTIONAL; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; SACCHAROMYCES CEREVISIAE; TUNISIA;

EID: 62949084482     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-8139-x     Document Type: Article

References (37)

1. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999; 11: 648-56.
2. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, BelaicheJ, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
3. Curran ME, Lau KF, Hampe J, Schreiber S, Bridger S,Macpherson AJ, Cardon LR, Sakul H, Harris TJ, Stokkers P,Van Deventer SJ, Mirza M, Raedler A, Kruis W, Meckler U, Theuer D, Herrmann T, Gionchetti P, Lee J, Mathew C, Lennard-Jones J. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998; 115: 1066-71.
4. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S,Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-8.
5. Bernstein CN, Orr K, Blanchard JF, Sargent M, Workman D. Developmentof an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn's disease. Can J Gastroenterol 2001; 15: 499.
6. Shanahan F. Crohn's disease. Lancet 2002; 359: 62-9.
7. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379: 821-3.
8. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-8.
9. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem 1999; 274: 14560-7.
10. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R,et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
11. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122: 867-74.
12. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
13. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.
14. O'Gorman and Woolson: On the efficacy of the rank transformation in stepwise logistic and discriminant analysis. Stat Med 1993; 12: 143-51.
15. Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, D'Incà R, Gionchetti P, Papih C, Riegler G, Vecchi M, Andriulli A. Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. Digest Liver Dis 2004; 36: 121-4.
16. Büning C, Molnar T, Nagy F, Lonovics J, Weltrich R, Bochow B, Genschel J, Schmidt H, Lochs H. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: Is Hungary different? World J Gastroenterol 2005; 11: 407-11.
17. Cukovic-Cavka S, Vermeire S, Hrstic I, Claessens G, Kolacek S, Jakic-Razumovic J, Krznaric Z, Grubelic K, Radic D, Misak Z, Jadresin O, Rutgeerts P, Vucelic B. NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship. Eur J Gastroenterol Hepatol. 2006; 18: 895-9.
18. Helio T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, Farkkila M, Krusius T, Kontula K. CARD15/NOD2 gene variants are associated with familially occuring and complicated forms of Crohn's disease. Gut 2003; 52: 558-62
19. Guo Q, Xia B, Jiang Y, Qü Y, Li J. NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J Gastroenterol 2004; 10: 1069-71.
20. Linskens RK, Mallant-Hent RC, Murillo LS, von Blomberg BME, Alizadeh BZ, Peña AS. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn's disease population. Digest Liver Dis 2004; 36: 29-34.
21. Van der Linde K, Boor PP, Houwing-Duistermaat JJ, Crusius BJ, Wilson PJ, Kuipers EJ, de Rooij FW. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies. Eur J Gastroenterol Hepatol 2007; 19: 449-59.
22. Zouiten-Mekki L, Zouali H, Boubaker J, Karoui S, Fekih M, Matri S, Hamzaoui S, Filali A, Chaabouni H. CARD15/NOD2 in a Tunisian Population with Crohn's Disease. Digest Dis Sci 2005; 50: 130-5.
23. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854-66.
24. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, Binder V et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-57.
25. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen DK, Karban A, Dassopoulos T et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis 2003: 281-9.
26. Bonen DK and Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124: 521-36.
27. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nunez G and Keshav S. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003; 125: 47-57.
28. Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, Zimmermann EM, Tretiakova M, Cho JH, Hart J et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003; 52: 1591-7.
29. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease inpatients with Crohn's disease. Gastroenterology 2002; 123: 679-88.
30. Dubinsky MC, Lee-Uy N, Lin Y-C et al. Synergism of NOD2/ CARD15 and ASCA (anti-Saccharomyces cerevisiae antibodies) contributes to disease behavior in pediatric Crohn's disease (CD) patients. Gastroenterology 2003; 124 (Suppl.): 1556.
31. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117-22.
32. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47: 487-96.
33. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to autoand microbial antigens. Gastroenterology 2002; 123: 689-99.
34. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, SeidmanEG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822-9.
35. Desreumaux P. Role of CARD15/Nod2 in the regulation of the host's response to pathogens in patients with Crohn's disease. Gastroenterol Clin Biol 2002; 26: 1065-6.
36. Vermeire S, Esters N, Pierik M, Joossens S, Claessens G, Vlietinck R, et al. Detailed study on phenotypical associations of NOD2/ CARD15 mutations in Crohn's disease. Gastroenterology 2002; 122: 297.
37. Sandborn WJ, Loftus Jr EV, Colombel JF, Fleming KA, SeiboldF, Homburger HA, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001; 7: 192-201.